



Spermosens AB (publ) to Host Live Q&A Webcast Following Recent Progress

Spermosens AB (publ) (“Spermosens” or the “Company”) today announces that it will host a live Q&A webcast on Thursday, 26 March 2026, at 12:00 CET. CEO Tore Duvold will address questions regarding the Company’s recent announcements and ongoing technical, clinical and commercial developments.

The session is organized as a dedicated Q&A to provide shareholders and other stakeholders with the opportunity to engage directly with the Company. Following the successful clinical validation of the JUNO-Checked system and the Company’s transition toward commercial partnerships, this webcast serves as a platform to discuss how these developments prepare the Company’s position in the global fertility diagnostics market.

To further enhance transparency and investor engagement, Spermosens intends to establish these Q&A sessions as a recurring event, typically held approximately one week after the publication of each quarterly report.

Webcast Details

- **Date:** Thursday, 26 March 2026
- **Time:** 12:00 CET
- **Language:** English and Swedish
- **Access Link:** <http://teams.microsoft.com/meet/33135525200798?p=PzGVIFSr0gwoxkA4Ly>

Participation and Submission of Questions

The webcast is open to all interested parties. Participants are invited to submit questions in advance to ensure a focused and productive session. The Company may consolidate similar queries to address as many topics as possible during the live broadcast.

- **Advance Questions:** Please email info@spermosens.com
- **Deadline for Submission:** Tuesday, 25 March 2026

For further information, please contact:

Tore Duvold, CEO

Email: info@spermosens.com

Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision and evaluations by measuring the sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatments strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company’s shares are listed on the

Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com